Molnupiravir Capsule

Molnupiravir functions as a potent ribonucleoside analog that disrupts viral replication by inducing lethal mutagenesis within the SARS-CoV-2 RNA genome, creating a targeted therapeutic synergy between the drug’s active metabolite and the virus’s own replication machinery. The capsule dosage form offers a critical clinical advantage by facilitating early, at-home intervention, which effectively bypasses the need for complex intravenous administration and reduces the overall strain on healthcare infrastructure. This oral delivery system ensures consistent systemic bioavailability and enhanced patient compliance, providing a stable and scalable pharmacological solution to mitigate the risk of disease progression in high-risk populations.